Elizabeth Dennis, MSN, APRN, FNP-C, discusses the overall survival benefit of amivantamab plus lazertinib in first-line epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer, what the COPERNICUS study shows about delivering subcutaneous amivantamab with proactive toxicity management, and how advanced practice providers can counsel patients on prophylaxis, set expectations, and use dose modifications to keep patients on treatment.
